Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Combination therapies for certain malignancies discussed by Idec

June 29, 2001

Phase I/II bladder cancer trial shows 59% complete response rate on MCC therapy

June 26, 2001

Phase I/II trial begins for malignant melanoma vaccine

June 26, 2001

Second multicenter phase I/II trial of GVAX for NSCLC

June 22, 2001

Patient enrollment completed in phase III trial of CeaVac

June 21, 2001

MabThera monoclonal antibody approved in Japan

June 21, 2001

ImClone reaches second milestone in phase III evaluation of BEC2

June 19, 2001

Phase III comparative trial of PEG-Intron and Intron A for CML completed

June 14, 2001

Extension of pemtumomab phase III trial announced following meeting with FDA

June 12, 2001

Dendreon expands phase III trials of Provenge for prostate cancer

June 12, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...